Published in J Med Chem on October 23, 2007
Three decades of beta-lactamase inhibitors. Clin Microbiol Rev (2010) 5.54
Solution-phase parallel synthesis of a multi-substituted benzo[b]thiophene library. J Comb Chem (2009) 0.91
Boronic Acid Transition State Inhibitors Active against KPC and Other Class A β-Lactamases: Structure-Activity Relationships as a Guide to Inhibitor Design. Antimicrob Agents Chemother (2016) 0.78
Permeation through the cell membrane of a boron-based β-lactamase inhibitor. PLoS One (2011) 0.78
Targeting class A and C serine β-lactamases with a broad-spectrum boronic acid derivative. J Med Chem (2014) 0.77
Biased retrieval of chemical series in receptor-based virtual screening. J Comput Aided Mol Des (2010) 0.75
ZINC--a free database of commercially available compounds for virtual screening. J Chem Inf Model (2005) 16.75
Predicting new molecular targets for known drugs. Nature (2009) 9.71
Relating protein pharmacology by ligand chemistry. Nat Biotechnol (2007) 6.61
A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. J Med Chem (2002) 5.67
Benchmarking sets for molecular docking. J Med Chem (2006) 5.57
High-throughput assays for promiscuous inhibitors. Nat Chem Biol (2005) 4.32
A specific mechanism of nonspecific inhibition. J Med Chem (2003) 3.93
Large-scale prediction and testing of drug activity on side-effect targets. Nature (2012) 3.88
Prediction of protein-ligand interactions. Docking and scoring: successes and gaps. J Med Chem (2006) 3.85
Evolution of an antibiotic resistance enzyme constrained by stability and activity trade-offs. J Mol Biol (2002) 3.71
Structure-based activity prediction for an enzyme of unknown function. Nature (2007) 3.65
Identification and prediction of promiscuous aggregating inhibitors among known drugs. J Med Chem (2003) 3.44
Small-molecule aggregates inhibit amyloid polymerization. Nat Chem Biol (2008) 2.98
A high-throughput screen for aggregation-based inhibition in a large compound library. J Med Chem (2007) 2.97
A model binding site for testing scoring functions in molecular docking. J Mol Biol (2002) 2.94
Directory of useful decoys, enhanced (DUD-E): better ligands and decoys for better benchmarking. J Med Chem (2012) 2.86
Metallo-beta-lactamases as emerging resistance determinants in Gram-negative pathogens: open issues. Int J Antimicrob Agents (2007) 2.61
A detergent-based assay for the detection of promiscuous inhibitors. Nat Protoc (2006) 2.58
Molecular characterization of extended-spectrum beta-lactamases produced by nosocomial isolates of Enterobacteriaceae from an Italian nationwide survey. J Clin Microbiol (2002) 2.56
Structure-based discovery of beta2-adrenergic receptor ligands. Proc Natl Acad Sci U S A (2009) 2.48
On functional and structural heterogeneity of VIM-type metallo-beta-lactamases. J Antimicrob Chemother (2003) 2.47
Multiple CTX-M-type extended-spectrum beta-lactamases in nosocomial isolates of Enterobacteriaceae from a hospital in northern Italy. J Clin Microbiol (2003) 2.45
Simple microdilution test for detection of metallo-beta-lactamase production in Pseudomonas aeruginosa. J Clin Microbiol (2002) 2.21
Predicting absolute ligand binding free energies to a simple model site. J Mol Biol (2007) 2.19
Deconstructing fragment-based inhibitor discovery. Nat Chem Biol (2006) 2.19
Automated docking screens: a feasibility study. J Med Chem (2009) 2.14
Molecular docking and high-throughput screening for novel inhibitors of protein tyrosine phosphatase-1B. J Med Chem (2002) 2.10
Ligand discovery from a dopamine D3 receptor homology model and crystal structure. Nat Chem Biol (2011) 2.10
Nosocomial infections caused by multidrug-resistant isolates of pseudomonas putida producing VIM-1 metallo-beta-lactamase. J Clin Microbiol (2002) 2.02
Emergence in Klebsiella pneumoniae and Enterobacter cloacae clinical isolates of the VIM-4 metallo-beta-lactamase encoded by a conjugative plasmid. Antimicrob Agents Chemother (2004) 1.98
Quantifying the relationships among drug classes. J Chem Inf Model (2008) 1.92
Structural bases of stability-function tradeoffs in enzymes. J Mol Biol (2002) 1.91
Trends in production of extended-spectrum beta-lactamases among enterobacteria of medical interest: report of the second Italian nationwide survey. J Clin Microbiol (2006) 1.91
Kinase inhibitors: not just for kinases anymore. J Med Chem (2003) 1.90
Predicting ligand binding affinity with alchemical free energy methods in a polar model binding site. J Mol Biol (2009) 1.90
The Enzyme Function Initiative. Biochemistry (2011) 1.87
Predicting substrates by docking high-energy intermediates to enzyme structures. J Am Chem Soc (2006) 1.81
An ultrahigh resolution structure of TEM-1 beta-lactamase suggests a role for Glu166 as the general base in acylation. J Am Chem Soc (2002) 1.81
Comprehensive mechanistic analysis of hits from high-throughput and docking screens against beta-lactamase. J Med Chem (2008) 1.81
Hierarchical docking of databases of multiple ligand conformations. Curr Top Med Chem (2005) 1.79
IMP-12, a new plasmid-encoded metallo-beta-lactamase from a Pseudomonas putida clinical isolate. Antimicrob Agents Chemother (2003) 1.77
Stoichiometry and physical chemistry of promiscuous aggregate-based inhibitors. J Am Chem Soc (2008) 1.74
Testing a flexible-receptor docking algorithm in a model binding site. J Mol Biol (2004) 1.73
Structure-based discovery of A2A adenosine receptor ligands. J Med Chem (2010) 1.71
Information decay in molecular docking screens against holo, apo, and modeled conformations of enzymes. J Med Chem (2003) 1.70
Structure-based discovery of a novel, noncovalent inhibitor of AmpC beta-lactamase. Structure (2002) 1.70
Promiscuous aggregate-based inhibitors promote enzyme unfolding. J Med Chem (2009) 1.68
Rapid context-dependent ligand desolvation in molecular docking. J Chem Inf Model (2010) 1.66
Quantifying biogenic bias in screening libraries. Nat Chem Biol (2009) 1.66
A pharmacological organization of G protein-coupled receptors. Nat Methods (2013) 1.65
Protein-protein docking with multiple residue conformations and residue substitutions. Protein Sci (2002) 1.61
Probing active site chemistry in SHV beta-lactamase variants at Ambler position 244. Understanding unique properties of inhibitor resistance. J Biol Chem (2006) 1.60
CTX-M-type extended-spectrum beta-lactamases in Italy: molecular epidemiology of an emerging countrywide problem. Antimicrob Agents Chemother (2006) 1.60
Molecular docking and ligand specificity in fragment-based inhibitor discovery. Nat Chem Biol (2009) 1.60
Rescoring docking hit lists for model cavity sites: predictions and experimental testing. J Mol Biol (2008) 1.57
Evolution of CTX-M-type beta-lactamases in isolates of Escherichia coli infecting hospital and community patients. Int J Antimicrob Agents (2005) 1.56
Proteus mirabilis bloodstream infections: risk factors and treatment outcome related to the expression of extended-spectrum beta-lactamases. Antimicrob Agents Chemother (2005) 1.55
Complementarity between a docking and a high-throughput screen in discovering new cruzain inhibitors. J Med Chem (2010) 1.54
Emerging extended-spectrum beta-lactamases in Proteus mirabilis. J Clin Microbiol (2002) 1.54
Structural milestones in the reaction pathway of an amide hydrolase: substrate, acyl, and product complexes of cephalothin with AmpC beta-lactamase. Structure (2002) 1.54
CAU-1, a subclass B3 metallo-beta-lactamase of low substrate affinity encoded by an ortholog present in the Caulobacter crescentus chromosome. Antimicrob Agents Chemother (2002) 1.52
Spread of bla(CTX-M-type) and bla(PER-2) beta-lactamase genes in clinical isolates from Bolivian hospitals. J Antimicrob Chemother (2006) 1.49
Soft docking and multiple receptor conformations in virtual screening. J Med Chem (2004) 1.47
Docking and chemoinformatic screens for new ligands and targets. Curr Opin Biotechnol (2009) 1.47
In silico molecular comparisons of C. elegans and mammalian pharmacology identify distinct targets that regulate feeding. PLoS Biol (2013) 1.47
Functional annotation and three-dimensional structure of Dr0930 from Deinococcus radiodurans, a close relative of phosphotriesterase in the amidohydrolase superfamily. Biochemistry (2009) 1.47
Virtual screening against metalloenzymes for inhibitors and substrates. Biochemistry (2005) 1.46
Structure-based approach for binding site identification on AmpC beta-lactamase. J Med Chem (2002) 1.45
Quantitative analyses of aggregation, autofluorescence, and reactivity artifacts in a screen for inhibitors of a thiol protease. J Med Chem (2010) 1.45
Decoys for docking. J Med Chem (2005) 1.43
Structure-based inhibitor discovery against adenylyl cyclase toxins from pathogenic bacteria that cause anthrax and whooping cough. J Biol Chem (2003) 1.43
Synergy and antagonism of promiscuous inhibition in multiple-compound mixtures. J Med Chem (2006) 1.42
Nanomolar inhibitors of AmpC beta-lactamase. J Am Chem Soc (2003) 1.41
Bacteremia due to Klebsiella pneumoniae isolates producing the TEM-52 extended-spectrum beta-lactamase: treatment outcome of patients receiving imipenem or ciprofloxacin. Clin Infect Dis (2003) 1.41
Structural basis for imipenem inhibition of class C beta-lactamases. Antimicrob Agents Chemother (2002) 1.39
Stability and equilibria of promiscuous aggregates in high protein milieus. Mol Biosyst (2007) 1.38
Chemical informatics and target identification in a zebrafish phenotypic screen. Nat Chem Biol (2011) 1.37
Identifying mechanism-of-action targets for drugs and probes. Proc Natl Acad Sci U S A (2012) 1.36
Molecular docking screens using comparative models of proteins. J Chem Inf Model (2009) 1.36
The 1.5-A structure of Chryseobacterium meningosepticum zinc beta-lactamase in complex with the inhibitor, D-captopril. J Biol Chem (2003) 1.35
First countrywide survey of acquired metallo-beta-lactamases in gram-negative pathogens in Italy. Antimicrob Agents Chemother (2008) 1.33
Structural consequences of the inhibitor-resistant Ser130Gly substitution in TEM beta-lactamase. Biochemistry (2005) 1.32
The chemical basis of pharmacology. Biochemistry (2010) 1.30
Structure-based discovery of prescription drugs that interact with the norepinephrine transporter, NET. Proc Natl Acad Sci U S A (2011) 1.29
Noncovalent interaction energies in covalent complexes: TEM-1 beta-lactamase and beta-lactams. Proteins (2002) 1.27
Parp1 localizes within the Dnmt1 promoter and protects its unmethylated state by its enzymatic activity. PLoS One (2009) 1.27
Structure-based ligand discovery for the protein-protein interface of chemokine receptor CXCR4. Proc Natl Acad Sci U S A (2012) 1.25
Structure and dynamics of CTX-M enzymes reveal insights into substrate accommodation by extended-spectrum beta-lactamases. J Mol Biol (2007) 1.22
Probing molecular docking in a charged model binding site. J Mol Biol (2006) 1.17
Colloidal aggregation affects the efficacy of anticancer drugs in cell culture. ACS Chem Biol (2012) 1.17
The structural bases of antibiotic resistance in the clinically derived mutant beta-lactamases TEM-30, TEM-32, and TEM-34. J Biol Chem (2002) 1.16
The deacylation mechanism of AmpC beta-lactamase at ultrahigh resolution. J Am Chem Soc (2006) 1.16